Lytix Biopharma (LYTIX) Q3 2026 earnings summary

Executive summary

• NeoLIPA Phase II met its primary pathological complete response endpoint in resectable melanoma; all 27 patients enrolled, with no new safety signals.

• FDA raised no objection to the proposed Phase III design; one well-designed study may support a US approval application, subject to overall results.

• Phase III preparation is underway, with partnership and alternative funding options being evaluated.

Financial highlights

• Q3 operating expenses were NOK 27.9 million versus NOK 24.3 million in Q3 2025; loss was NOK 26.1 million versus NOK 23.3 million.

• Direct R&D expenses were NOK 14.3 million; excluding NOK 3.1 million in non-cash share-based compensation, operating expenses were NOK 24.8 million.

• Q3 cash burn was NOK 24.1 million, down from ~NOK 29 million in each of Q1 and Q2 2026.

Outlook and guidance

• The proposed Phase III study will compare ruxotemitide plus pembrolizumab with pembrolizumab alone before surgery in high-recurrence-risk melanoma.

• Phase III protocol development, CRO selection and site assessment are progressing.

• ALETTA, a Phase II study of ruxotemitide with ipilimumab and nivolumab in resectable stage III melanoma, is on track to begin in early 2027.

• Full NeoLIPA results are scheduled for presentation at ESMO Immuno-Oncology on December 15, 2026; LTX-401 is being prepared for clinical entry.